Aarti Drugs Ltd

Aarti Drugs Limited has a debt-to-equity ratio of 0.45, indicating a relatively conservative capital structure. The company's liquidity position is characterized as medium, with a current ratio of 1.6, suggesting it can cover its short-term liabilities with its short-term assets. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively. In terms of profitability, Aarti Drugs Limited has a return on equity (ROE) of 12.28% and a return on assets (ROA) of 6.53%. These figures suggest that the company is generating a reasonable return for its shareholders and effectively utilizing its assets. However, these returns should be compared to the industry median to determine if they are above or below average. The company's revenue is distributed across two geographical segments: India and Out of India. While the exact revenue concentration for each segment is not provided, the company's operations in both domestic and international markets suggest a diversified revenue base. This diversification can help mitigate risks associated with regional economic fluctuations. Aarti Drugs Limited's growth trajectory is influenced by its product portfolio and market expansion. The company is developing new products such as alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin, which could drive future revenue. The company's capital expenditure of -1.77 billion INR indicates a reduction in investment in physical assets, which may be a strategic decision to focus on other areas of growth. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully. The low dilution risk indicates that the company is not expected to issue a significant number of new shares in the near term, which is favorable for existing shareholders. Recent events and filings do not provide specific details on the company's recent activities. However, the company's focus on developing new products and its operations in both domestic and international markets suggest a strategic approach to growth and market expansion.